Literature DB >> 8472811

A retrospective analysis of bleeding complications in 438 patients with acute leukaemia during the years 1972-1991.

E Törnebohm1, D Lockner, C Paul.   

Abstract

The incidence and mortality of bleeding complications have been investigated in 438 patients with acute leukaemia consolidated either by chemotherapy (n = 241) or by bone marrow transplantation (n = 197). Bleeding signs on admission were found in 38% of the chemotherapy-treated group. Haemorrhagic deaths during the 1st month were seen in 10%. The majority of the major bleedings were localized intracranial, but gastrointestinal haemorrhages were also common. The platelet count was significantly lower (40 x 10(9)/l versus 69 x 10(9)/l, p < 0.001) and the leukocyte count significantly higher (31.2 x 10(9)/l versus 11.6 x 10(9)/l, p < 0.001) in the group with bleeding complications than in those without. The haemorrhagic mortality in patients consolidated with chemotherapy compared with transplant patients was similar, 23% and 19%. The majority of the lethal haemorrhages in the latter group were observed in patients undergoing allogenic bone marrow transplantation after engraftment. Septicaemia, graft-versus-host and venous occlusive disease were contributing factors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8472811     DOI: 10.1111/j.1600-0609.1993.tb00085.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  5 in total

1.  Co-occurrence of hyperleukocytosis and elevated fibrin-fibrinogen degradation product levels is a risk factor for early intracranial hemorrhage in patients with de novo acute leukemia.

Authors:  Kunimoto Ichikawa; Yoko Edahiro; Akihiko Gotoh; Kazuhide Iiduka; Norio Komatsu; Michiaki Koike
Journal:  Int J Hematol       Date:  2016-07-25       Impact factor: 2.490

2.  Management of hemostatic complications in acute leukemia: Guidance from the SSC of the ISTH.

Authors:  Tzu-Fei Wang; Robert S Makar; Darko Antic; Jerrold H Levy; James D Douketis; Jean M Connors; Marc Carrier; Jeffrey I Zwicker
Journal:  J Thromb Haemost       Date:  2020-12       Impact factor: 5.824

3.  A multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11 in acute myelogenous leukemia.

Authors:  Kensuke Usuki; Akio Urabe; Yasuo Ikeda; Yasuo Ohashi; Hideaki Mizoguchi; Fumimaro Takaku
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

4.  Lesions of the central nervous system in leukemia: Pathological and magnetic resonance imaging features at presentation in 14 patients.

Authors:  Jing Liu; Yaming Wang; Xuefei Sun; Shuo Liu; Zhenkun Yu; Nan Ji; Shengjun Sun; Yuanbo Liu
Journal:  Oncol Lett       Date:  2017-10-16       Impact factor: 2.967

5.  Case Report: ANXA2 Associated Life-Threatening Coagulopathy With Hyperfibrinolysis in a Patient With Non-APL Acute Myeloid Leukemia.

Authors:  Leo Ruhnke; Friedrich Stölzel; Lisa Wagenführ; Heidi Altmann; Uwe Platzbecker; Sylvia Herold; Andreas Rump; Evelin Schröck; Martin Bornhäuser; Johannes Schetelig; Malte von Bonin
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.